Latest news from the FASST trial

Jun 8, 2016 | FASST, Projects, Study

inventivaAs mentioned earlier, the FASST trial is a phase 2 clinical trial sponsored by Inventiva Pharma.

The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.

Read latest newsletter on the research: FASST Newsletter, May2016


FESCA news & eventsnews & events

FESCA 2019 Newsletter

FESCA 2019 Newsletter

We are happy to share with you the FESCA 2019 Newsletter. Read some inspiring stories from our members, and how they celebrated World Scleroderma Day 2019.

Help us to keep smiling

Help us to keep smiling

We invite you from all over the world to post a picture/video with smiles on social medias like twitter, facebook, instagram etc with the hashtag #ScleroSmile

Share This